THOMAS G WIGGANS
CIK 1208907 · Chief Executive Officer · last filed 2026-06-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.47M
Companies
10
Total Filings
114
Lifetime Open-Market Net
-$7.30M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PCRX | Director | — | $26.81 | — | $0 | 1 | 2026-06-12 |
| JSPRW | Director | 46,000 | $0.01 | $557 | $130.7K | 7 | 2025-09-24 |
| ANNX | Director | — | $4.97 | — | $0 | 5 | 2025-06-09 |
| CymaBay Therapeutics, Inc. (CBAY) Delisted | Director | — | $32.48 | — | $0 | 5 | 2024-03-22 |
| PARDES BIOSCIENCES, INC. (PRDS) Delisted | Chief Executive Officer | 0 | $2.16 | $0 | $53.0K | 6 | 2023-08-31 |
| Forma Therapeutics Holdings, Inc. (FMTX) Delisted | Director | 0 | $20.01 | $0 | $0 | 4 | 2022-10-14 |
| DERM | CEO & Chairman of the Board | 233,506 | $6.31 | $1.47M | -$5.33M | 40 | 2019-08-19 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | Director | 8,115 | — | — | -$2.07M | 19 | 2013-05-23 |
| Pernix Sleep, Inc. (SOMX) Delisted | Director | 15,286 | — | — | -$80.9K | 13 | 2012-07-03 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Director | — | $0.18 | — | $0 | 4 | 2011-06-03 |
Recent Filings · Page 2 of 12
114 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-11-30 | JSPRW | Buy (P) | +10,000 | $6.5K | EDGAR |
| 2023-11-22 | JSPRW | Buy (P) | +10,000 | $6.4K | EDGAR |
| 2023-11-20 | JSPRW | Buy (P) | +30,000 | $18.2K | EDGAR |
| 2023-11-02 | JSPRW | Grant (A) | — | $0 | EDGAR |
| 2023-08-31 | PARDES BIOSCIENCES, INC. (PRDS) Delisted | Mixed | −50,000 | $0 | EDGAR |
| 2023-06-12 | ANNX | Grant (A) | — | $0 | EDGAR |
| 2023-02-03 | PARDES BIOSCIENCES, INC. (PRDS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-01-27 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-12-07 | PARDES BIOSCIENCES, INC. (PRDS) Delisted | Buy (P) | +12,500 | $13.6K | EDGAR |
| 2022-12-05 | PARDES BIOSCIENCES, INC. (PRDS) Delisted | Buy (P) | +37,500 | $39.4K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.